Herombopag Treated T-DM1 Induced Platelet Reduction
Recruiting now · Phase 2
Conditions studied: Thrombocytopenia
In brief
This is a single-arm study planned to enroll 56 breast cancer patients who experienced grade 2 or higher thrombocytopenia following prior chemotherapy and achieved normalization (platelet count ≥100 × 109/L and ≥200 × 109/L) through intervention.
Key facts
- Study ID
- NCT07257809
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- People needed
- 56
- Starts
- 2025-10-13
- Expected to finish
- 2027-09-26
- Last updated by the study team
- 2025-12-02
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Sun Yat-sen Memorial Hospital — Guangzhou, Guangdong, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.